TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31304887

Group type: EXPERIMENTAL
Intervention: Mindfulness-based relapse prevention group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard relapse prevention group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (marijuana or opiates users)
Number of subjects: 0
Study: 29456191

Group type: EXPERIMENTAL
Intervention: 20 mg/kg azithromycin (low-dose)
Number of subjects: 583

Group type: COMPARATOR
Intervention: 30 mg/kg azithromycin (standard-dose)
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: Both groups (20 mg/kg and 30 mg/kg azithromycin)
Number of subjects: 583
Study: 26970111

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention (8-week program with mindful spin-bike training)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 47
Study: 24597610

Group type: EXPERIMENTAL
Intervention: Soft orange contact lenses (SOCL)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Chronic exposure to reduced short wavelength light (SOCL for two weeks)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Chronic reduced blue light exposure
Number of subjects: 15
Study: 21720441

Group type: EXPERIMENTAL
Intervention: Beverage (energy-matched fruits and vegetables)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Solid (energy-matched fruits and vegetables)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Solid fruits and vegetables (lean group)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Solid fruits and vegetables (overweight/obese group)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Beverage (lean group)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Beverage (overweight/obese group)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Beverage (obese group)
Number of subjects: 34
Study: 20140434

Group type: EXPERIMENTAL
Intervention: Nasogastric tube in place (n = 29)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No nasogastric tube (n = 31)
Number of subjects: 60
Study: 17883845

Group type: EXPERIMENTAL
Intervention: Structured programme for treating depression
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual management
Number of subjects: 400
Study: 16383068

Group type: EXPERIMENTAL
Intervention: 50 mg/100 ml alcohol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 80 mg/100 ml alcohol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Alcohol placebo
Number of subjects: 16
Study: 12230153

Group type: EXPERIMENTAL
Intervention: Friends (5-year-olds)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Nonfriends (5-year-olds)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Friends (4-year-olds)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Nonfriends (4-year-olds)
Number of subjects: 217
Study: 10936121

Group type: EXPERIMENTAL
Intervention: Red signal observed by color flow imaging
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Hemodynamic studies in patients with RF signal
Number of subjects: 191
Study: 8737213

Group type: EXPERIMENTAL
Intervention: Fat-rich meal (600 ml, approximately 4000 kJ)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich meal (600 ml, approximately 4000 kJ)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Balanced meal (600 ml, approximately 4000 kJ)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Water (600 ml)
Number of subjects: 14
Study: 1412115

Group type: EXPERIMENTAL
Intervention: Resistance breathing training using a resistive breathing device (PFLEX) for 10 minutes five times daily with progressively larger resistances.
Number of subjects: 82

Group type: COMPARATOR
Intervention: Sham device providing minimal resistance.
Number of subjects: 82
Study: 3895960

Group type: EXPERIMENTAL
Intervention: Single-dose treatment with 500 mg clotrimazole
Number of subjects: 199

Group type: COMPARATOR
Intervention: 6-day treatment with 100 mg clotrimazole
Number of subjects: 199
Study: 31882650

Group type: EXPERIMENTAL
Intervention: Locally disordered crystal
Number of subjects: 2

Group type: COMPARATOR
Intervention: Ordered crystal
Number of subjects: 2
Study: 30037277

Group type: EXPERIMENTAL
Intervention: Vascular Endothelial Growth Factor (VEGF)
Number of subjects: 100
Study: 26372481

Group type: EXPERIMENTAL
Intervention: Doravirine 25 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Doravirine 200 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 24629048

Group type: EXPERIMENTAL
Intervention: Co-viewing with parents
Number of subjects: 99

Group type: COMPARATOR
Intervention: Co-viewing with friends
Number of subjects: 99
Study: 22732313

Group type: EXPERIMENTAL
Intervention: 0.3-ppm ozone for 2 hours while intermittently exercising
Number of subjects: 23

Group type: COMPARATOR
Intervention: Clean air
Number of subjects: 23
Study: 20152065

Group type: EXPERIMENTAL
Intervention: Individual CBT treatment
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Group CBT treatment
Number of subjects: 102

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 102
Study: 18049345

Group type: EXPERIMENTAL
Intervention: QI-Therapy
Number of subjects: 1188

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 1188

Group type: COMPARATOR
Intervention: QI-Meds
Number of subjects: 1188
Study: 16288704

Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg/d orally for 1 month)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12126818

Group type: EXPERIMENTAL
Intervention: External irradiation combined with immediate androgen suppression (Goserelin 3.6 mg subcutaneously every 4 weeks for 3 years, and Cyproterone acetate 150 mg orally for 1 month starting 1 week before goserelin)
Number of subjects: 415

Group type: COMPARATOR
Intervention: External irradiation alone (50 Gy radiation delivered to the pelvis over 5 weeks, and 20 Gy over 2 weeks as a prostatic boost)
Number of subjects: 415
Study: 10402684

Group type: EXPERIMENTAL
Intervention: Anxious-ambivalent attachment style
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Avoidant attachment style
Number of subjects: 3
Study: 7487847

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT) without explicit exposure instructions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exposure and response prevention treatment without cognitive restructuring procedures
Number of subjects: 0
Study: 2154431

Group type: EXPERIMENTAL
Intervention: Azithromycin (250 mg bd on day 1 and 250 mg once daily on days 2 to 5)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Erythromycin (500 mg qid for ten days)
Number of subjects: 101
Study: 31358533

Group type: EXPERIMENTAL
Intervention: Barley Recombinant Inbred Diverse Germplasm Population (BRIDG6)
Number of subjects: 6160

Group type: EXPERIMENTAL
Intervention: Haplotype-based analysis of HvPpd-H1
Number of subjects: 6160

Group type: EXPERIMENTAL
Intervention: Subsampling strategies for QTL detection
Number of subjects: 6160
Study: 28087371

Group type: EXPERIMENTAL
Intervention: hs-cTnI
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: hs-cTnT
Number of subjects: 133

Group type: COMPARATOR
Intervention: cTnI
Number of subjects: 133
Study: 26094950

Group type: EXPERIMENTAL
Intervention: Full serving of rice
Number of subjects: 39

Group type: COMPARATOR
Intervention: Half serving of rice
Number of subjects: 39
Study: 23819612

Group type: EXPERIMENTAL
Intervention: Inorganic adsorbent (modified zeolite)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Organic adsorbent (esterified glucomannans)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed adsorbent (inorganic and organic components plus enzymes)
Number of subjects: 0
Study: 22075527

Group type: EXPERIMENTAL
Intervention: Family Healthware intervention
Number of subjects: 3283

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3283
Study: 19240996

Group type: EXPERIMENTAL
Intervention: Neoadjuvant hormonal therapy (NHT)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: NHT and adjuvant hormonal therapy (HT)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: LHRH agonists
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Short-term NHT
Number of subjects: 170
Study: 17302021

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave treatment (ESWT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ESWT
Number of subjects: 0
Study: 14720160

Group type: EXPERIMENTAL
Intervention: Septal approach
Number of subjects: 20

Group type: COMPARATOR
Intervention: Posterior approach
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 20
Study: 11172836

Group type: COMPARATOR
Intervention: Progesterone 600 mg/d for 3 weeks after a positive hCG result (Control)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: No progesterone supplementation (Intervention)
Number of subjects: 400
Study: 10461102

Group type: EXPERIMENTAL
Intervention: Posteroventral pallidotomy
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Ventrolateral thalamotomy
Number of subjects: 33
Study: 8168773

Group type: EXPERIMENTAL
Intervention: Pregnant women with a history of substance abuse
Number of subjects: 225

Group type: COMPARATOR
Intervention: Pregnant women without a history of substance abuse
Number of subjects: 225
Study: 3202502

Group type: EXPERIMENTAL
Intervention: Intravenous aminophylline (A)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (S)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Salbutamol (S) added to aminophylline (A)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Aminophylline (A) added to salbutamol (S)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Salbutamol (S)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Aminophylline (A)
Number of subjects: 8
Study: 27573207

Group type: EXPERIMENTAL
Intervention: Antipsychotics
Number of subjects: 16
Study: 28325148

Group type: EXPERIMENTAL
Intervention: M2000 (500 mg twice daily for 12 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no M2000 treatment)
Number of subjects: 40
Study: 26122282

Group type: EXPERIMENTAL
Intervention: DP+R method (digital photographs plus recall)
Number of subjects: 91

Group type: COMPARATOR
Intervention: TDEE(DLW) (total daily energy expenditure assessed by doubly labeled water)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: DP+R method
Number of subjects: 91
Study: 23683069

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 20496981

Group type: EXPERIMENTAL
Intervention: Information plus self-regulation
Number of subjects: 255

Group type: COMPARATOR
Intervention: Information only
Number of subjects: 255
Study: 18828814

Group type: EXPERIMENTAL
Intervention: Non-submerged implants (ITI)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Submerged implants (3i)
Number of subjects: 31
Study: 16573704

Group type: EXPERIMENTAL
Intervention: Budesonide 200 microg once daily via Turbuhaler
Number of subjects: 1981

Group type: COMPARATOR
Intervention: Placebo once daily via Turbuhaler
Number of subjects: 1981
Study: 14698701

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 75
Study: 11108748

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue plasminogen activator (rtPA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8805890

Group type: EXPERIMENTAL
Intervention: Heat challenge (overheating)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (non-susceptible piglets)
Number of subjects: 8
Study: 1381164

Group type: EXPERIMENTAL
Intervention: Alpha-blockers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6396969

Group type: EXPERIMENTAL
Intervention: 600 mg piridoxilate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Traffic noise (placebo)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 600 mg piridoxilate (with traffic noise)
Number of subjects: 10
Study: 31985066

Group type: EXPERIMENTAL
Intervention: SRP + adjunct probiotic therapy (PT) in non-chewers (group 4)
Number of subjects: 126

Group type: COMPARATOR
Intervention: SRP alone in non-chewers (group 3)
Number of subjects: 126

Group type: COMPARATOR
Intervention: SRP alone in shamma users (group 1)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: SRP + adjunct probiotic therapy (PT) in shamma users (group 2)
Number of subjects: 126
Study: 30577220

Group type: EXPERIMENTAL
Intervention: Renal Transplantation (RTx)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Hemodialysis (HD)
Number of subjects: 84
Study: 26197241

Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccination
Number of subjects: 2183

Group type: EXPERIMENTAL
Intervention: Screening procedure
Number of subjects: 2183
Study: 24818626

Group type: EXPERIMENTAL
Intervention: Olmesartan
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 85
Study: 22399084

Group type: EXPERIMENTAL
Intervention: 4.5g arginine
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 9g arginine
Number of subjects: 23

Group type: COMPARATOR
Intervention: Historical control group (not specified dosage)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Malnourished patients
Number of subjects: 23
Study: 20391240

Group type: EXPERIMENTAL
Intervention: Healthy eating television programmes
Number of subjects: 6
Study: 18597808

Group type: EXPERIMENTAL
Intervention: Visual search task with varying presentation times (100, 200, 400, 800 ms) and background slant (0 degrees or 60 degrees)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual search task with contextual information learned across trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual search task with presentation times less than 100 ms
Number of subjects: 0
Study: 31319908

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 650
Study: 12514150

Group type: EXPERIMENTAL
Intervention: 1.25 mg x kg(‐1) tramadol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2.5 mg x kg(‐1) tramadol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 3.75 mg x kg(‐1) tramadol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5 mg x kg(‐1) tramadol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (Groups II-IV)
Number of subjects: 60
Study: 10225072

Group type: EXPERIMENTAL
Intervention: Multiple Nerve Stimulation (MNS)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Transarterial (TA)
Number of subjects: 101
Study: 8544795

Group type: COMPARATOR
Intervention: Regimen C (Vincristine + Actinomycin D)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regimen D (Vincristine + Actinomycin D + Doxorubicin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regimen DD-RT (Vincristine + Actinomycin D + Cyclophosphamide + Whole Lung Radiation Therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regimen J (Vincristine + Actinomycin D + Doxorubicin + Whole Lung Radiation Therapy)
Number of subjects: 0
Study: 1830551

Group type: EXPERIMENTAL
Intervention: Quinapril (10, 20, or 40 mg day‐1)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study: 6361990

Group type: EXPERIMENTAL
Intervention: J5 antiserum
Number of subjects: 100

Group type: COMPARATOR
Intervention: Pre-immune serum (control)
Number of subjects: 100
Study: 31138168

Group type: EXPERIMENTAL
Intervention: Povu Poa intervention (new handwashing station dispensing foaming soap and rinse water, combined with behavior change promotion)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Povu Poa intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (schools that had not yet received the intervention)
Number of subjects: 30
Study: 28102978

Group type: EXPERIMENTAL
Intervention: First-episode psychosis (FEP) patients
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Antipsychotic-naive patients
Number of subjects: 113

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Family history of type 2 diabetes mellitus
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Dyslipidemia
Number of subjects: 113
Study: 26138109

Group type: EXPERIMENTAL
Intervention: Dorsal onlay buccal mucosal graft urethroplasty
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ventral onlay buccal mucosal graft urethroplasty
Number of subjects: 80
Study: 23278292

Group type: EXPERIMENTAL
Intervention: Sociological investigations into the social construction of diseases, surveillance systems, public health governance, and public/media responses
Number of subjects: 0
Study: 21883004

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg)
Number of subjects: 13
Study: 18974700

Group type: EXPERIMENTAL
Intervention: Air plethysmography (APG) assessment of venous filling index (VFI)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Air plethysmography (APG) assessment of venous volume, ejection fraction, and residual volume fraction
Number of subjects: 135
Study: 17065871

Group type: EXPERIMENTAL
Intervention: Short course to improve communication skills (small-group teaching with lecture, discussion, and role-play)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Short course to improve communication skills
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 56
Study: 12927634

Group type: EXPERIMENTAL
Intervention: Negative affect induced by exposure to three brief shocks
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Negative affect elicited by the threat of shock without presentation
Number of subjects: 127

Group type: COMPARATOR
Intervention: Neutral affect, with no intervention
Number of subjects: 127
Study: 11370546

Group type: EXPERIMENTAL
Intervention: Cold shower (n = 8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Without cold shower (n = 8)
Number of subjects: 16
Study: 9403542

Group type: EXPERIMENTAL
Intervention: A‐CVC (antibiotic- and antiseptic-coated central venous catheter)
Number of subjects: 282

Group type: COMPARATOR
Intervention: S‐CVC (standard central venous catheter)
Number of subjects: 282
Study: 8218755

Group type: EXPERIMENTAL
Intervention: 10 mg cisapride q.d.s.
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: 20 mg cisapride b.d.
Number of subjects: 155

Group type: COMPARATOR
Intervention: 150 mg ranitidine b.d.
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Overall reflux symptom score
Number of subjects: 155
Study: 3034107

Group type: EXPERIMENTAL
Intervention: Etomidate/fentanyl (n = 12)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Methohexital/fentanyl (n = 9)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Midazolam/fentanyl (n = 8)
Number of subjects: 29
Study: 31674134

Group type: EXPERIMENTAL
Intervention: 0.5-mg intravitreal ranibizumab injection
Number of subjects: 24

Group type: COMPARATOR
Intervention: Subconjunctival saline injection (placebo)
Number of subjects: 24
Study: 29944646

Group type: EXPERIMENTAL
Intervention: Point-of-sex HIV self-testing (HIVST)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Previous HIV self-testing experiences
Number of subjects: 400
Study: 27965209

Group type: EXPERIMENTAL
Intervention: Chlorthalidone/amiloride combination pill
Number of subjects: 730

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 730
Study: 24090282

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (M)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Nifedipine (N)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Indomethacin (I)
Number of subjects: 301
Study: 22763268

Group type: EXPERIMENTAL
Intervention: Quark RMR
Number of subjects: 24

Group type: COMPARATOR
Intervention: Deltatrac
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CCM Express
Number of subjects: 24
Study: 21587082

Group type: EXPERIMENTAL
Intervention: PET-CT
Number of subjects: 149

Group type: COMPARATOR
Intervention: Invasive mediastinal staging (mediastinoscopy alone or combined with thoracotomy)
Number of subjects: 149
Study: 17479312

Group type: EXPERIMENTAL
Intervention: Electrothermal bipolar vessel sealing (EBVS) device (group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: UltraSonic Shears (USS) device (group B)
Number of subjects: 50
Study: 16870915

Group type: EXPERIMENTAL
Intervention: Standard medical management and once-weekly medication dispensing
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Standard medical management and thrice-weekly medication dispensing
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Enhanced medical management and thrice-weekly medication dispensing
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 166
Study: 14566214

Group type: EXPERIMENTAL
Intervention: Transdermal buspirone patches
Number of subjects: 64

Group type: COMPARATOR
Intervention: Matching placebo patches
Number of subjects: 64
Study: 10928726

Group type: EXPERIMENTAL
Intervention: Moderation‐Oriented Cue Exposure (MOCE)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Behavioral Self‐Control Training (BSCT)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Self-reports of alcohol consumption and problems
Number of subjects: 91
Study: 8769938

Group type: EXPERIMENTAL
Intervention: GTPN (TPN containing 0.23 g glutamine/kg.day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: CTPN (standard TPN)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GTPN
Number of subjects: 20
Study: 1430300

Group type: EXPERIMENTAL
Intervention: diltiazem SR 120 mg
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: diltiazem SR 240 mg
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: diltiazem SR 360 mg
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: diltiazem SR 480 mg
Number of subjects: 275

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 275
Study: 3950055

Group type: EXPERIMENTAL
Intervention: 0.5 mg triazolam tablet in the morning (7 AM)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.5 mg triazolam tablet in the evening (10 PM)
Number of subjects: 10
Study: 30073795

Group type: COMPARATOR
Intervention: Etoposide/carboplatin (control arm)
Number of subjects: 455
Study: 26683790

Group type: EXPERIMENTAL
Intervention: Prazosin (16 mg)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96